Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors

INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Josifovski Tatjana [verfasserIn] Radošević-Jelić Ljiljana [verfasserIn] Tulić Cane [verfasserIn] Milošević Aleksandar [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; srp

Erschienen:	2008

Schlagwörter:	prostate cancer radical radiotherapy disease relapse prognostic factors

Übergeordnetes Werk:	In: Srpski Arhiv za Celokupno Lekarstvo - Serbian Medical Society, 2010, 136(2008), 7-8, Seite 373-378
Übergeordnetes Werk:	volume:136 ; year:2008 ; number:7-8 ; pages:373-378

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.2298/SARH0808373J

Katalog-ID:	DOAJ011186976

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ011186976
003	DE-627
005	20230310033232.0
007	cr uuu---uuuuu
008	230225s2008 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2298/SARH0808373J \|2 doi
035			\|a (DE-627)DOAJ011186976
035			\|a (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a srp
100	0		\|a Josifovski Tatjana \|e verfasserin \|4 aut
245	1	0	\|a Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors
264		1	\|c 2008
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities.
650		4	\|a prostate cancer
650		4	\|a radical radiotherapy
650		4	\|a disease relapse
650		4	\|a prognostic factors
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Radošević-Jelić Ljiljana \|e verfasserin \|4 aut
700	0		\|a Tulić Cane \|e verfasserin \|4 aut
700	0		\|a Milošević Aleksandar \|e verfasserin \|4 aut
773	0	8	\|i In \|t Srpski Arhiv za Celokupno Lekarstvo \|d Serbian Medical Society, 2010 \|g 136(2008), 7-8, Seite 373-378 \|w (DE-627)637421205 \|w (DE-600)2577665-4 \|x 24060895 \|7 nnns
773	1	8	\|g volume:136 \|g year:2008 \|g number:7-8 \|g pages:373-378
856	4	0	\|u https://doi.org/10.2298/SARH0808373J \|z kostenfrei
856	4	0	\|u https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb \|z kostenfrei
856	4	0	\|u http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0370-8179 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 136 \|j 2008 \|e 7-8 \|h 373-378

Indexfelder

author_variant	j t jt r j l rjl t c tc m a ma
matchkey_str	article:24060895:2008----::iesrlpeatraiardohrpopottcneaay
hierarchy_sort_str	2008
publishDate	2008
allfields	10.2298/SARH0808373J doi (DE-627)DOAJ011186976 (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb DE-627 ger DE-627 rakwb eng srp Josifovski Tatjana verfasserin aut Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities. prostate cancer radical radiotherapy disease relapse prognostic factors Medicine R Radošević-Jelić Ljiljana verfasserin aut Tulić Cane verfasserin aut Milošević Aleksandar verfasserin aut In Srpski Arhiv za Celokupno Lekarstvo Serbian Medical Society, 2010 136(2008), 7-8, Seite 373-378 (DE-627)637421205 (DE-600)2577665-4 24060895 nnns volume:136 year:2008 number:7-8 pages:373-378 https://doi.org/10.2298/SARH0808373J kostenfrei https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb kostenfrei http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf kostenfrei https://doaj.org/toc/0370-8179 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 136 2008 7-8 373-378
spelling	10.2298/SARH0808373J doi (DE-627)DOAJ011186976 (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb DE-627 ger DE-627 rakwb eng srp Josifovski Tatjana verfasserin aut Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities. prostate cancer radical radiotherapy disease relapse prognostic factors Medicine R Radošević-Jelić Ljiljana verfasserin aut Tulić Cane verfasserin aut Milošević Aleksandar verfasserin aut In Srpski Arhiv za Celokupno Lekarstvo Serbian Medical Society, 2010 136(2008), 7-8, Seite 373-378 (DE-627)637421205 (DE-600)2577665-4 24060895 nnns volume:136 year:2008 number:7-8 pages:373-378 https://doi.org/10.2298/SARH0808373J kostenfrei https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb kostenfrei http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf kostenfrei https://doaj.org/toc/0370-8179 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 136 2008 7-8 373-378
allfields_unstemmed	10.2298/SARH0808373J doi (DE-627)DOAJ011186976 (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb DE-627 ger DE-627 rakwb eng srp Josifovski Tatjana verfasserin aut Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities. prostate cancer radical radiotherapy disease relapse prognostic factors Medicine R Radošević-Jelić Ljiljana verfasserin aut Tulić Cane verfasserin aut Milošević Aleksandar verfasserin aut In Srpski Arhiv za Celokupno Lekarstvo Serbian Medical Society, 2010 136(2008), 7-8, Seite 373-378 (DE-627)637421205 (DE-600)2577665-4 24060895 nnns volume:136 year:2008 number:7-8 pages:373-378 https://doi.org/10.2298/SARH0808373J kostenfrei https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb kostenfrei http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf kostenfrei https://doaj.org/toc/0370-8179 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 136 2008 7-8 373-378
allfieldsGer	10.2298/SARH0808373J doi (DE-627)DOAJ011186976 (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb DE-627 ger DE-627 rakwb eng srp Josifovski Tatjana verfasserin aut Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities. prostate cancer radical radiotherapy disease relapse prognostic factors Medicine R Radošević-Jelić Ljiljana verfasserin aut Tulić Cane verfasserin aut Milošević Aleksandar verfasserin aut In Srpski Arhiv za Celokupno Lekarstvo Serbian Medical Society, 2010 136(2008), 7-8, Seite 373-378 (DE-627)637421205 (DE-600)2577665-4 24060895 nnns volume:136 year:2008 number:7-8 pages:373-378 https://doi.org/10.2298/SARH0808373J kostenfrei https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb kostenfrei http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf kostenfrei https://doaj.org/toc/0370-8179 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 136 2008 7-8 373-378
allfieldsSound	10.2298/SARH0808373J doi (DE-627)DOAJ011186976 (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb DE-627 ger DE-627 rakwb eng srp Josifovski Tatjana verfasserin aut Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities. prostate cancer radical radiotherapy disease relapse prognostic factors Medicine R Radošević-Jelić Ljiljana verfasserin aut Tulić Cane verfasserin aut Milošević Aleksandar verfasserin aut In Srpski Arhiv za Celokupno Lekarstvo Serbian Medical Society, 2010 136(2008), 7-8, Seite 373-378 (DE-627)637421205 (DE-600)2577665-4 24060895 nnns volume:136 year:2008 number:7-8 pages:373-378 https://doi.org/10.2298/SARH0808373J kostenfrei https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb kostenfrei http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf kostenfrei https://doaj.org/toc/0370-8179 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 136 2008 7-8 373-378
language	English
source	In Srpski Arhiv za Celokupno Lekarstvo 136(2008), 7-8, Seite 373-378 volume:136 year:2008 number:7-8 pages:373-378
sourceStr	In Srpski Arhiv za Celokupno Lekarstvo 136(2008), 7-8, Seite 373-378 volume:136 year:2008 number:7-8 pages:373-378
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	prostate cancer radical radiotherapy disease relapse prognostic factors Medicine R
isfreeaccess_bool	true
container_title	Srpski Arhiv za Celokupno Lekarstvo
authorswithroles_txt_mv	Josifovski Tatjana @@aut@@ Radošević-Jelić Ljiljana @@aut@@ Tulić Cane @@aut@@ Milošević Aleksandar @@aut@@
publishDateDaySort_date	2008-01-01T00:00:00Z
hierarchy_top_id	637421205
id	DOAJ011186976
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ011186976</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310033232.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2298/SARH0808373J</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ011186976</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">srp</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Josifovski Tatjana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radical radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disease relapse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognostic factors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radošević-Jelić Ljiljana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tulić Cane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milošević Aleksandar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Srpski Arhiv za Celokupno Lekarstvo</subfield><subfield code="d">Serbian Medical Society, 2010</subfield><subfield code="g">136(2008), 7-8, Seite 373-378</subfield><subfield code="w">(DE-627)637421205</subfield><subfield code="w">(DE-600)2577665-4</subfield><subfield code="x">24060895</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:136</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:7-8</subfield><subfield code="g">pages:373-378</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2298/SARH0808373J</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0370-8179</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">136</subfield><subfield code="j">2008</subfield><subfield code="e">7-8</subfield><subfield code="h">373-378</subfield></datafield></record></collection>
author	Josifovski Tatjana
spellingShingle	Josifovski Tatjana misc prostate cancer misc radical radiotherapy misc disease relapse misc prognostic factors misc Medicine misc R Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors
authorStr	Josifovski Tatjana
ppnlink_with_tag_str_mv	@@773@@(DE-627)637421205
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	24060895
topic_title	Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors prostate cancer radical radiotherapy disease relapse prognostic factors
topic	misc prostate cancer misc radical radiotherapy misc disease relapse misc prognostic factors misc Medicine misc R
topic_unstemmed	misc prostate cancer misc radical radiotherapy misc disease relapse misc prognostic factors misc Medicine misc R
topic_browse	misc prostate cancer misc radical radiotherapy misc disease relapse misc prognostic factors misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Srpski Arhiv za Celokupno Lekarstvo
hierarchy_parent_id	637421205
hierarchy_top_title	Srpski Arhiv za Celokupno Lekarstvo
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)637421205 (DE-600)2577665-4
title	Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors
ctrlnum	(DE-627)DOAJ011186976 (DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb
title_full	Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors
author_sort	Josifovski Tatjana
journal	Srpski Arhiv za Celokupno Lekarstvo
journalStr	Srpski Arhiv za Celokupno Lekarstvo
lang_code	eng srp
isOA_bool	true
recordtype	marc
publishDateSort	2008
contenttype_str_mv	txt
container_start_page	373
author_browse	Josifovski Tatjana Radošević-Jelić Ljiljana Tulić Cane Milošević Aleksandar
container_volume	136
format_se	Elektronische Aufsätze
author-letter	Josifovski Tatjana
doi_str_mv	10.2298/SARH0808373J
author2-role	verfasserin
title_sort	disease relapses after radical radiotherapy of prostate cancer: analysis of prognostic factors
title_auth	Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors
abstract	INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities.
abstractGer	INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities.
abstract_unstemmed	INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	7-8
title_short	Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors
url	https://doi.org/10.2298/SARH0808373J https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf https://doaj.org/toc/0370-8179
remote_bool	true
author2	Radošević-Jelić Ljiljana Tulić Cane Milošević Aleksandar
author2Str	Radošević-Jelić Ljiljana Tulić Cane Milošević Aleksandar
ppnlink	637421205
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.2298/SARH0808373J
up_date	2024-07-03T18:57:28.578Z
_version_	1803585373952016384
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ011186976</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310033232.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2298/SARH0808373J</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ011186976</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ11d3354a216b4be8bfd3a3e8f8bd5beb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">srp</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Josifovski Tatjana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">INTRODUCTION Although there is no consensus on which is the best option in prostate cancer treatment, these patients could be successfully treated with radiotherapy. Regarding some prognostic factors, it is possible today to classify prostate cancer patients into several risk groups for clinical and biochemical relapse, and therefore to choose the right treatment modality. OBJECTIVE The objective in our study was to analyze the impact of tumor stage and grade, previous transurethral resection of the prostate (TUR), initial prostate specific antigen (PSA) level and age on disease relapse after radical radiotherapy of the prostate cancer. METHOD Between January 1991 and December 2005, a clinical, retrospective study was performed at the Radiotherapy Department of the Institute for Oncology and Radiology of Serbia, which included 283 patients with prostate cancer treated only with radical radiotherapy. During regular follow-up we analyzed response to treatment and disease relapse. RESULTS After radical radiotherapy disease relapse more often occurred (with statistical significance) in patients with locally advanced tumor (stage C 35% vs. A 13% vs. B 19%), low tumor grade (grade III 38% vs. grade II 23% vs. grade I 17%), initial PSA level over 10 ng/ml (29%) and over 20 ng/ml (37%) compared to 11% in the patients with initial PSA level below10 ng/ml, and patients of lower age (less than 55 years 50% vs. 16% in patients over 70 years). CONCLUSION Tumor stage C, low tumor grade (grade II-III), initial PSA level over 10 ng/ml (over 20 ng/ml) and younger age are poor prognostic factors for disease relapse. In this case, radiotherapy as monotherapy is not an adequate approach, and it needs to be combined with other therapeutic modalities.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">radical radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disease relapse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognostic factors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radošević-Jelić Ljiljana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tulić Cane</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milošević Aleksandar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Srpski Arhiv za Celokupno Lekarstvo</subfield><subfield code="d">Serbian Medical Society, 2010</subfield><subfield code="g">136(2008), 7-8, Seite 373-378</subfield><subfield code="w">(DE-627)637421205</subfield><subfield code="w">(DE-600)2577665-4</subfield><subfield code="x">24060895</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:136</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:7-8</subfield><subfield code="g">pages:373-378</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2298/SARH0808373J</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/11d3354a216b4be8bfd3a3e8f8bd5beb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790808373J.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0370-8179</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">136</subfield><subfield code="j">2008</subfield><subfield code="e">7-8</subfield><subfield code="h">373-378</subfield></datafield></record></collection>
score	7.399089

Nicht das Richtige dabei?

Schreiben Sie uns!

Disease relapses after radical radiotherapy of prostate cancer: Analysis of prognostic factors

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?